Published in Neurochem Int on June 12, 2008
Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Eur J Neurosci (2015) 1.52
New approaches to the treatment of frontotemporal lobar degeneration. Curr Opin Neurol (2008) 1.12
Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med (2011) 0.93
Implicating calpain in tau-mediated toxicity in vivo. PLoS One (2011) 0.91
Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions. ASN Neuro (2011) 0.89
Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. J Cell Mol Med (2009) 0.87
Inhibition of calpain prevents NMDA-induced cell death and beta-amyloid-induced synaptic dysfunction in hippocampal slice cultures. Br J Pharmacol (2010) 0.81
β-Amyloid carrying the Dutch mutation has diverse effects on calpain-mediated toxicity in hippocampal neurons. Mol Med (2012) 0.81
Calpain dysregulation in Alzheimer's disease. ISRN Biochem (2012) 0.79
Synaptic therapy in Alzheimer's disease: a CREB-centric approach. Neurotherapeutics (2015) 0.79
Neuronal degeneration, synaptic defects, and behavioral abnormalities in tau₄₅₋₂₃₀ transgenic mice. Neuroscience (2014) 0.77
A novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice. Sci Rep (2016) 0.77
The Neurotoxic TAU45-230 Fragment Accumulates in Upper and Lower Motor Neurons in Amyotrophic Lateral Sclerosis Subjects. Mol Med (2016) 0.75
Cholesterol in the Pathogenesis of Alzheimer's, Parkinson's Diseases and Autism: Link to Synaptic Dysfunction. Acta Naturae (2017) 0.75
Tau45-230 association with the cytoskeleton and membrane-bound organelles: functional implications in neurodegeneration. Neuroscience (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 20.07
Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol (1994) 11.55
The calpain system. Physiol Rev (2003) 9.95
Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci U S A (1979) 8.41
The distribution of tau in the mammalian central nervous system. J Cell Biol (1985) 7.47
Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A (1986) 6.56
Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature (2000) 4.31
Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau) Proc Natl Acad Sci U S A (1986) 4.26
Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol (1994) 3.13
Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A (2002) 3.04
Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A (1993) 2.58
beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron (1995) 2.56
The carboxyl third of tau is tightly bound to paired helical filaments. Neuron (1988) 2.31
Seminars in medicine of the Beth Israel Hospital, Boston. beta-Amyloid and the pathogenesis of Alzheimer's disease. N Engl J Med (1991) 2.24
Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci (2004) 1.99
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A (1993) 1.92
Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J (1993) 1.91
A dynamin GTPase mutation causes a rapid and reversible temperature-inducible locomotion defect in C. elegans. Proc Natl Acad Sci U S A (1997) 1.82
The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci (2005) 1.72
Calpain-mediated mGluR1alpha truncation: a key step in excitotoxicity. Neuron (2007) 1.61
Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. J Biol Chem (2003) 1.55
Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis (2001) 1.55
Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease. Proc Natl Acad Sci U S A (1984) 1.51
beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem (2006) 1.50
Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol Cell Neurosci (1997) 1.43
Spectrin and calpain: a 'target' and a 'sniper' in the pathology of neuronal cells. Cell Mol Life Sci (2005) 1.41
Microtubule formation and neurite growth in cerebellar macroneurons which develop in vitro: evidence for the involvement of the microtubule-associated proteins, MAP-1a, HMW-MAP2 and Tau. Brain Res Dev Brain Res (1989) 1.35
Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci (2004) 1.34
Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett (1999) 1.27
Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J Biol Chem (2005) 1.25
Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. Neuroscience (2007) 1.24
Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Am J Pathol (2004) 1.24
m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. Neurosci Lett (1998) 1.20
N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem (2007) 1.15
Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3. J Biol Chem (2005) 1.10
Activation of the L voltage-sensitive calcium channel by mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. J Biol Chem (1999) 1.05
Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. Stroke (1994) 1.04
The ultrastructural localization of calcium-activated protease "calpain" in rat brain. Synapse (1988) 1.02
Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett (1998) 1.01
Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci (2003) 0.99
Role of calpain and caspase in beta-amyloid-induced cell death in rat primary septal cultured neurons. Neuropharmacology (2007) 0.93
mu-Calpain activation, DNA fragmentation, and synergistic effects of caspase and calpain inhibitors in protecting hippocampal neurons from ischemic damage. Brain Res (2000) 0.92
The C-terminal domain of glutamate receptor subunit 1 is a target for calpain-mediated proteolysis. Neuroscience (1996) 0.91
Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus. Neurochem Int (2006) 0.91
Calpain-mediated regulation of NMDA receptor structure and function. Brain Res (1998) 0.91
The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia. Pain (2004) 0.90
Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. Neurochem Int (2007) 0.87
Mu-calpain is functionally required for alpha-processing of Alzheimer's beta-amyloid precursor protein. Biochem Biophys Res Commun (2005) 0.85
Calcium influx into human neuroblastoma cells induces ALZ-50 immunoreactivity: involvement of calpain-mediated hydrolysis of protein kinase C. J Neurochem (1996) 0.84
Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability. J Med Chem (2003) 0.83
Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders. Neurochem Int (2007) 0.81
Inhibition of calpain-mediated cell death by a novel peptide inhibitor. Exp Neurol (2006) 0.78
Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem (2005) 3.06
Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A (2002) 3.04
The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci (2005) 1.72
Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol (2012) 1.60
Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology (2007) 1.53
beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem (2006) 1.50
Electrophysiological and in vivo characterization of A-317567, a novel blocker of acid sensing ion channels. Pain (2005) 1.46
LIMK1 regulates Golgi dynamics, traffic of Golgi-derived vesicles, and process extension in primary cultured neurons. Mol Biol Cell (2004) 1.35
Regulation of neurotransmitter release by synapsin III. J Neurosci (2002) 1.34
Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J Biol Chem (2005) 1.25
Localization of histamine H4 receptors in the central nervous system of human and rat. Brain Res (2008) 1.24
Expression and subcellular localization of Ror tyrosine kinase receptors are developmentally regulated in cultured hippocampal neurons. J Neurosci Res (2003) 1.04
Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity. J Neurosci (2009) 1.02
H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol Biochem Behav (2009) 1.01
Targeted wild-type and jerker espins reveal a novel, WH2-domain-dependent way to make actin bundles in cells. J Cell Sci (2006) 1.01
Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM. J Neurophysiol (2003) 0.99
Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2. J Cell Sci (2005) 0.99
A rare polymorphism affects a mitogen-activated protein kinase site in synapsin III: possible relationship to schizophrenia. Biol Psychiatry (2004) 0.96
Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem (2009) 0.95
Monosodium iodoacetate-induced joint pain is associated with increased phosphorylation of mitogen activated protein kinases in the rat spinal cord. Mol Pain (2011) 0.95
Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment. Neurosci Lett (2006) 0.94
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J Med Chem (2004) 0.92
A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats. Pharmacol Biochem Behav (2005) 0.92
Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease. Brain Res (2009) 0.91
Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating. Psychopharmacology (Berl) (2006) 0.91
Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem (2005) 0.91
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization. J Pharmacol Exp Ther (2002) 0.91
A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor. CNS Drug Rev (2006) 0.90
Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology (2005) 0.89
Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J Pharmacol Exp Ther (2003) 0.88
alpha1 Integrin activation: a link between beta-amyloid deposition and neuronal death in aging hippocampal neurons. J Neurosci Res (2004) 0.88
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther (2012) 0.88
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem (2006) 0.88
Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models. J Med Chem (2008) 0.87
YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol (2003) 0.87
A-350619: a novel activator of soluble guanylyl cyclase. Life Sci (2003) 0.85
Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists. Bioorg Med Chem Lett (2006) 0.85
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem (2008) 0.85
Emerging pharmacologic approaches for the treatment of lower urinary tract disorders. J Pharmacol Exp Ther (2004) 0.85
Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands. J Med Chem (2008) 0.84
Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5). Biochem Pharmacol (2004) 0.84
Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin Exp Pharmacol Physiol (2004) 0.84
Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems. Brain Res (2010) 0.84
In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. Neuropharmacology (2010) 0.83
MAPK signal transduction pathway mediates agrin effects on neurite elongation in cultured hippocampal neurons. J Neurobiol (2003) 0.83
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. in vivo characterization. J Pharmacol Exp Ther (2002) 0.83
Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization. J Pharmacol Exp Ther (2012) 0.83
A-412997 is a selective dopamine D4 receptor agonist in rats. Pharmacol Biochem Behav (2005) 0.82
Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity. Biochem Pharmacol (2007) 0.82
Analgesic activity of metabotropic glutamate receptor 1 antagonists on spontaneous post-operative pain in rats. Eur J Pharmacol (2007) 0.81
A cell-based microarrayed compound screening format for identifying agonists of G-protein-coupled receptors. Anal Biochem (2003) 0.81
β-Amyloid carrying the Dutch mutation has diverse effects on calpain-mediated toxicity in hippocampal neurons. Mol Med (2012) 0.81
Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav (2005) 0.81
Membrane cholesterol modulates {beta}-amyloid-dependent tau cleavage by inducing changes in the membrane content and localization of N-methyl-D-aspartic acid receptors. J Biol Chem (2010) 0.81
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction. J Med Chem (2006) 0.81
Association of Catsper1 or -2 with Ca(v)3.3 leads to suppression of T-type calcium channel activity. J Biol Chem (2006) 0.80
Differential subcellular localization of Ror tyrosine kinase receptors in cultured astrocytes. Glia (2004) 0.80
Estrogen-induced changes in the microtubular system correlate with a decreased susceptibility of aging neurons to beta amyloid neurotoxicity. Mol Cell Neurosci (2003) 0.80
Synthesis and functional activity of (2-aryl-1-piperazinyl)-N-(3-methylphenyl)acetamides: selective dopamine D4 receptor agonists. Bioorg Med Chem (2004) 0.80
Diagnosing the nutritional status of schoolchildren: a comparison between Brazilian and international criteria. J Pediatr (Rio J) (2008) 0.80
Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis. Psychopharmacology (Berl) (2011) 0.79
Enhancement of apomorphine-induced penile erection in the rat by a selective alpha(1D)-adrenoceptor antagonist. Br J Pharmacol (2002) 0.79
Rigidified 2-aminopyrimidines as histamine H4 receptor antagonists: effects of substitution about the rigidifying ring. Bioorg Med Chem Lett (2010) 0.79
The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. Neuropharmacology (2012) 0.79
Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation. Neuropharmacology (2005) 0.79
[3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor. Eur J Pharmacol (2004) 0.79
Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem (2004) 0.78
Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction. Neurourol Urodyn (2003) 0.78
In vitro studies on a class of quinoline containing histamine H3 antagonists. Bioorg Med Chem Lett (2010) 0.78
Dissociation between post-surgical pain behaviors and spinal Fos-like immunoreactivity in the rat. Eur J Pharmacol (2006) 0.77
Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists. Bioorg Med Chem Lett (2007) 0.77
Synthesis and evaluation of 3-aryl piperidine analogs as potent and efficacious dopamine D4 receptor agonists. Bioorg Med Chem (2005) 0.77
ABT-866, a novel alpha(1A)-adrenoceptor agonist with antagonist properties at the alpha(1B)- and alpha(1D)-adrenoceptor subtypes. Eur J Pharmacol (2002) 0.77
A robust and high-capacity [(35)S]GTPgammaS binding assay for determining antagonist and inverse agonist pharmacological parameters of histamine H(3) receptor ligands. Assay Drug Dev Technol (2008) 0.77
Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator. J Pharmacol Sci (2006) 0.77
Cloning and characterization of the monkey histamine H3 receptor isoforms. Eur J Pharmacol (2008) 0.76
K-ATP opener-mediated attenuation of spontaneous bladder contractions in ligature-intact, partial bladder outlet obstructed rats. Life Sci (2003) 0.76
Oral involvement in autoimmune bullous diseases. Clin Dermatol (2011) 0.76
Pharmacological characterization of A-960656, a histamine H₃ receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain. Eur J Pharmacol (2012) 0.76
Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity. Epilepsia (2005) 0.76
2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist. Neuropharmacology (2005) 0.75
Population dynamics and diet of the madamango Sea catfish Cathorops spixii (Agassiz, 1829) (Siluriformes: Ariidae) in a tropical bight in Southeastern Brazil. PLoS One (2013) 0.75
Antagonism of supraspinal histamine H3 receptors modulates spinal neuronal activity in neuropathic rats. J Pharmacol Exp Ther (2012) 0.75
Aβ toxicity in primary cultured neurons. Methods Mol Biol (2011) 0.75
N-[3-(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J Med Chem (2002) 0.75
Meeting report for the ASPET Ray Fuller Symposium: lower urinary tract disorders: physiology, pharmacology, and therapeutic approaches. J Pharmacol Exp Ther (2002) 0.75
Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist. Psychopharmacology (Berl) (2013) 0.75
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships. J Med Chem (2009) 0.75
Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligand. Bioorg Med Chem Lett (2004) 0.75